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Abstract: Congenital sensorineural hearing loss may occur in association with inborn pigmentary
defects of the iris, hair, and skin. These conditions, named auditory-pigmentary disorders (APDs),
represent extremely heterogeneous hereditary diseases, including Waardenburg syndromes,
oculocutaneous albinism, Tietz syndrome, and piebaldism. APDs are part of the neurocristopathies,
a group of congenital multisystem disorders caused by an altered development of the neural crest
cells, multipotent progenitors of a wide variety of different lineages, including those differentiating
into peripheral nervous system glial cells and melanocytes. We report on clinical and genetic findings
of two monozygotic twins from a large Albanian family who showed a complex phenotype featured
by sensorineural congenital deafness, severe neuropsychiatric impairment, and inborn pigmentary
defects of hair and skin. The genetic analyzes identified, in both probands, an unreported co-occurrence
of a new heterozygous germline pathogenic variant (c.2484 + 5G > T splicing mutation) in the KIT
gene, consistent with the diagnosis of piebaldism, and a heterozygous deletion at chromosome 15q13.3,
responsible for the neuropsychiatric impairment. This case represents the first worldwide report
of dual locus inherited syndrome in piebald patients affected by a complex auditory-pigmentary
multisystem phenotype. Here we also synthesize the clinical and genetic findings of all known
neurocristopathies characterized by a hypopigmentary congenital disorder.
Keywords: genodermatoses; genetic skin disorders; auditory-pigmentary disorders; neurocristopathies;
piebaldism; multilocus syndrome; KIT; 15q13.3 deletion
1. Introduction
Neurocristopathies (NCP) represent a complex group of inborn conditions associated with a
wide range of multiorgan congenital diseases determined by an aberration in growth, migration, and
differentiation of neural crest (NC) cells [1,2]. NC is a transient, multipotent cell population that
generates a broad spectrum of numerous cell types, including melanocytes of the skin and hair follicles,
neurons, and glial cells. As a result, patients with NCP develop an extensive range of multisystem
abnormalities such as skin and hair pigmentation defects, neurological and ocular disorders [1–3].
Among NCP, Hirschsprung, DiGeorge, Treacher-Collins, CHARGE, Axenfeld-Rieger, and Goldenhar
syndromes are mainly featured by cardiac, auditory, eye, neurological, urinary, craniofacial defects,
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and/or missing enteric ganglia [1,2]. Waardenburg syndrome (WS), oculocutaneous albinism (OCA),
Tietz syndrome (TS) and piebaldism (PBT) represent a subgroup of NCP, termed auditory-pigmentary
disorders (APDs). All APDs are clinically characterized by inborn skin and hair pigmentary anomalies.
They can also be associated with a wide and heterogeneous spectrum of auditory, neurological, and
ocular disorders [4–6]. Precisely, congenital sensorineural hearing loss (SNHL) is a very common feature
in WS and TS patients; conversely, it has been described more rarely in PBT and OCA subjects [4–6].
Table 1 synthesizes the clinical and genetic findings of all known neural crest–associated diseases
characterized by hypopigmentary congenital disorders [3–15].
Here, we describe clinical features and genetic data of two Caucasian monozygotic twins affected
by an unreported neuro-cutaneous phenotype characterized by inborn SNHL, a congenital disorder of
pigmentation and severe neuropsychiatric impairment.
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Table 1. Neural crest–associated diseases with hypopigmentary congenital disorders.
Name of Syndrome Genetic Disorder 1 Frequency
Clinical Findings 2
Skin and Cutaneous Annexes Non-Cutaneous
Waardenburg
Syndrome, Type 1
WS1 AD Gene PAX3
(2q36.1)
Incidence 1:20,000–40,000 births
(3–5% of congenital SNHL)
Poliosis (45%)
Early graying of the scalp hair (45%)
Congenital leukoderma (30%):
white skin patches on the face, trunk,
or limbs; hyperpigmented borders
may be present
Facial dysmorphism: Dystopia canthorum (100%): lateral
displacement of the inner canthi, high nasal root
(50–100%), medial eyebrow flare (60–70%)
Eyes: Heterochromia iridium (15–30%), hypoplastic or
brilliant blue irides (15%)
Neurological signs: SNHL (60%)
Occasional findings: spina bifida, cleft lip and palate
Waardenburg
Syndrome, Type 2
WS2 AD
Genes
MITF
15–20%
(3p14-p13)
SOX10
15%
(22q13.1)
SNAI2
very rare
(8q11.21)
Poliosis (15–30%)
Early graying of the scalp hair (30%)
Congenital leukoderma (5–12%)
Facial dysmorphism: Dystopia canthorum not present
(0%), high nasal root (0–14%), medial eyebrow flare (10%)
Neurological signs: SNHL (80–90%)
Eyes: Heterochromia iridium/(50%), hypoplastic blue
irides (3–23%)
Kallmann syndrome (anosmia, hypogonadism) in
carriers of mutation in SOX10 gene
Occasional findings: temporal bone abnormalities,
ganglionic megacolon, abnormality of the kidney and/or
the pulmonary artery, ptosis, telecanthus
Waardenburg
syndrome, Type 3
(Klein–Waardenburg
syndrome)
WS3 AD/AR
Gene PAX3 (2q36.1)
The rarest form of all
WS types
Hypopigmentation abnormalities of
hair and skin like WS1
Facial dysmorphism: like WS1
Eyes: like WS1, blepharophimosis (80–100%)
Neurological signs: SNHL, microcephaly (80–100%)
Limb anomalies: hypoplasia of the musculoskeletal
system, flexion contractures, carpal bone fusion,
syndactyly (80–100%)
Waardenburg
syndrome, Type 4
(Waardenburg-Shah
syndrome)
WS4 AR
Genes
EDNRB (13q22.3)
EDN3
(20q13.32)
SOX10
(22q13.1)
Prevalence: <1/106
Hypopigmentation abnormalities of
hair and skin like WS1
Facial dysmorphism: like WS1
Eyes: like WS1
Neurological signs: SNHL, Hirschsprung disease
Neurologic Waardenburg-Shah syndrome or PCWH
(Peripheral demyelinating neuropathy, central
dysmyelinating leukodystrophy, Waardenburg syndrome
and Hirschsprung disease). Association of the features of
WS4 and neurological impairment (neonatal hypotonia,
intellectual deficit, nystagmus, progressive spasticity,
ataxia, and epilepsy)
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Table 1. Cont.
Name of Syndrome Genetic Disorder 1 Frequency
Clinical Findings 2
Skin and Cutaneous Annexes Non-Cutaneous
Tietz syndrome
TS AD
dominant negative
effect
Gene
MITF
(3p14-p13)
Extremely rare (only few
families described)
Generalized uniform
hypopigmentation of the skin
(100%): the affected patients are born
“snow white”, then they gradually
gain some pigmentation (fair skin)
and they may have reddish freckles
Hair, eyebrows and eyelashes
(100%): blonde to white
Facial dysmorphism: not present
Neurological signs: severe congenital bilateral
SNHL (100%)
Eyes: blue eyes and hypopigmented fundi
Piebaldism
PBT AD
Genes
KIT
(4q12)
SNAI2
(8q11.21)
Incidence <1:20,000
Congenital well-demarked,
symmetrical, non-pigmented
patches involving the skin of the
face, trunk, arms and legs.
The skin lesions are usually stable
during life, although
hyperpigmented dots or macules may
appear within or at their margins
Café-au-lait macules can be present
(co-occurrence with
neurofibromatosis type 1).
Poliosis is traditionally known as
“white forelock” (localized patch of
white hair in a group of hair follicles).
It is often triangular and may be the
only manifestation of PBT in 80–90%
of c-Kit carriers.
Leukotrichia of eyebrows
and eyelashes
Heterochromia irides, neurological impairment and
SNHL occur rarely.
Spritz et al. described a South African female affected by
severe SNHL and PBT, carrying a heterozygous missense
change (p.R796G) in the KIT gene [12]
Human homozygosity for the KIT germline mutations has
been reported in a severe multisystem phenotype
consisting of hypopigmented skin and hair, blue irides,
neurodevelopmental delay, hypotonia, SNHL, anemia,
brachycephaly, and clinodactyly [13,14]
Medicina 2019, 55, 345 5 of 10
Table 1. Cont.
Name of Syndrome Genetic Disorder 1 Frequency
Clinical Findings 2
Skin and Cutaneous Annexes Non-Cutaneous
Oculocutaneous
Albinism
OCA
OCA is a heterogeneous
and autosomal recessive disorder
NOTE: All types of OCA are
associated with increased risk of
precancerous skin lesions and skin
tumors (non-melanoma and
melanoma skin cancers)
NOTE: Congenital SNHL has been described in a few
OCA patients as a consequence of the co-occurrence of AR
deafness and OCA
OCA1A, OCA1B
AR
Gene
TYR
(11q14.3)
The most common subtype
in Caucasians, accounting for
about 50% of cases worldwide
Incidence 1:20,000/40,000 births
Generalized congenital
hypopigmentation of the skin
(white or very light)
White or nearly white or light
yellow/blonde hair, eyebrows and
eyelashes
Ocular signs: nystagmus; reduced iris pigment with iris
translucency; reduced retinal pigment with visualization
of the choroidal blood vessels on ophthalmoscopic
examination; foveal hypoplasia with reduction in visual
acuity, strabismus, blue irides that darken to green/hazel
or light brown/tan with age
OCA2, AR
Gene
OCA2
(15q12)
The most common OCA type in
Africa accounting
for 30% of cases worldwide
Incidence 1:20,000/40.000 births
Generalized congenital
hypopigmentation of the skin
(never white but range from very fair
to near normal). The skin color may
darken over time and sun exposure
Lightly pigmented hair, eyebrows
and eyelashes (never white but range
from light yellow to blonde to brown),
the hair color may darken with age
Ocular signs: like OCA1 with visual acuity usually better
than OCA1
Iris color: it ranges from blue to brown
OCA3, AR
Gene
TYRP1
(9p23)
Prevalence: 1/8.500 individuals
in African population
It is extremely rare in
Caucasian population
Generalized light or freckled or
light brown skin
Ginger-red or blonde hair
Ocular signs: like OCA1
Iris color: blue or brown
OCA4, AR
Gene
SLC45A2
(5p13.3)
OCA6, AR
SLC24A2
(9p22.1)
OCA5, AR
Gene unknown
(4q24)
OCA7, AR
Gene C10ORF11
(10q22.2)
Extremely rare
Generalized congenital
hypopigmentation of the skin
(never white, range from creamy
white to near normal)
Lightly pigmented hair, eyebrows
and eyelashes (never white but range
from silvery to golden or near normal)
The hair color may darken with age.
Ocular signs: like OCA1 with visual acuity usually better
than OCA1. OCA6 and 7 patients do not present an
obvious change in the pigmentation patterns.
Iris color: it ranges from blue to brown
Note 1: AD autosomal dominant, AR autosomal recessive. Note 2: the average penetrance of clinical signs is specified in brackets.
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2. Case Presentation
2.1. Clinical Findings
The probands, two 21 year old male monozygotic twins (IV-3 and IV-4, Figure 1), were referred to
our department for dermatologic evaluation. Clinical examination revealed numerous regularly shaped
hypopigmented patches on the face, trunk, and upper and lower extremities, mainly distributed on the
frontal side of the body (Figure 2). Several hyperpigmented dots and macules were present within and
along the margins of the leukoderma areas. Both probands had blond hair with tufts of leukotrichia on
the scalp, eyelids, and eyebrows. Both had blue eyes, but only IV-4 showed heterochromia at the right
iris. They did not have dystopia canthorum, nor were they dysmorphic.
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Figure 1. Family pedigree and sequence analysis. Top: the genealogical tree of the two probands 
(monozygotic twins). Squares represent male subjects, circles represent female subjects. The numbers 
inside symbols indicate the number of subjects with the same sex. A transversal line indicates dead 
subjects. The legend box indicates the features associated with each filled quadrant of the symbol. 
Arrows indicate the probands. DD and ID are developmental disabilities and intellectual disability, 
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Figure 1. Family pedigree and sequence analysis. Top: the genealogical tree of the two probands
(monozygotic twins). Squares represent male subjects, circles represent female subjects. The numbers
inside symbols indicate the number of subjects with the same sex. A transversal line indicates dead
subjects. The legend box indicates the features associated with each filled quadrant of the symbol.
Arrows indicate the probands. DD and ID are developmental disabilities and intellectual disability,
respectively. The symbol ”+/–“ indicates a heterozygous state for the c.2484+5G > T KIT variant.
Bottom: Sanger sequences of the variant in a wild type and the IV-3 proband. Below we indicate the
exon 17 last bases (capital letters) and the intron 17 region (lower case letters).
Patients suffered from profound bilateral congenital SNHL, neurodevelopmental delay, severe
intellectual disability, and c ildhood onset of grafted psychosis. They dis layed speech disorders and
social isolation.
Probands were the first children of an unrelated couple of Albanian parents, coming from a small
community of central Albania. The mother (Figure 1, III-6), a 50 year old woman, reported that her
sons’ depigmented lesions were congenital and did not evolve. Her dermatological examination also
showed inborn hypopigmented skin and hair lesions, similar but less extended than those of her
children (Figure 2). None of her family members presented any neurological sign.
We could not perform a dermatological examination on the father, (Figure 1, III-5), a 55 year old
man affected by a severe form of adult-onset schizophrenia. His wife reported he did not present
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any skin or hair anomalies. On the other hand, several males and female relatives of III-6 (Figure 1)
presented similar skin and hair congenital lesions shown in the probands. A dermatological exam
of the probands’ maternal uncle (III-9) and his 6 month old daughter (IV-6), showed diffuse areas of
leukoderma and leukotrichia in the absence of neurological symptoms.
Clinical skin and hair features of the probands suggested a diagnosis of PBT, generally associated
with mutations in the KIT gene (MIM *164920, NM_000222).Medicina 2019, 55, x FOR PEER REVIEW 5 of 9 
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2.2. Materials and Methods
Genomic DNA was isolated from peripheral blood u ing a standard procedure (Qiag n,
Hilden, Germ ny) and quantified by Nanodrop spectrophotometer (Thermo Scientific Waltham,
Massachusett , USA). The KIT gene (NM_000222.2) coding exons were mplified a d sequenced using
Sanger sequencing.
We perfor d array-CGH with a 60K whole-genome oligonucleotide microarray follow ng
the manufacture ’s protocol (Agilent Technologi , Santa Clara, California, USA). Slides were
scann d using a G2565BA scanner and analyzed using Agil nt CGH Analytics software ver.
4.0.81 (Agilent Technologies) with the statistical lg rithm ADM-2 and a sensitivity thr sh
of 6.0. At least three consecutive aberrant probes id tified significant copy-number changes.
We compared our find ngs to known CNVs listed in th Database of Genomic Variants (DGV,
http://projects.tcag.ca/v riation) and in the DECIPHER database (https://decipher.s nger.ac.uk/).
TaqMan real-time quantitative PCR (qPCR) ana ysis was used to measure copy number
variants at 3q23 and 15q13.2q13.3 in g nomic DNA as follows: (a) 3q23 duplication, GK5
(NM_001039547.2) exon 16, primer 5′-agactggaagctccctgaaa; 5′-tcccac tacatgaaagcaca; #38 UPL
probe (Roche Diagnostics); (b) 15q13.2q13.3 deletion, CHRNA7 (NM_000746) exon 2, primers
5′-caatgactcgcaaccactca; 5′-atccacgtccatgatctgc; #7 UPL probe (Roche Diagnostics); and (c) RNaseP
reference gene, VIC-labeled pre-designed TaqMan gene expression assays (P/N 4316844, Applied
Biosystems). We carried out the reaction with an ABI 7500 Fast real-time PCR machine using the ABI
TaqMan Universal PCR master mix according to the manufacturer’s instructions (Applied Biosystems,
Foster City, USA). Efficiencies of the assays were similar and in a range of 90% to 110%. Samples from
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affected individuals and unrelated healthy controls were run in triplicate. The mean Ct value was used
for calculations using the ∆∆Ct method [16].
2.3. Genetic Findings
The sequence of the coding exons and flanking intron sequences of the KIT gene allowed the
identification of a heterozygous c.2484+5G>T change in intron 17. The variant was not reported in the
Genome Aggregation Database (GnomAD; http://gnomad.broadinstitute.org/), and it was predicted
to reduce the score of the donor splice site of exon 17 (MutationTaster, http://www.mutationtaster.
org/: pathogenic; Splice Site Prediction by Neural Network, http://www.fruitfly.org/seq_tools/splice.
html: from 0.99 to 0.35; transcript-inferred pathogenicity score doi:10.1038/s41467-017-00141-2: 0.93,
pathogenic; CADD score = 22.4, representing <1% of the most pathogenic mutations; Human Splicing
Finder 3.1 = donor splice site broken wild type vs. mutant 86.87 to 74.56, −14.17%). The Human
Splicing Finder 3.1 software also predicts the complete loss of an SRp55 splicing enhancer binding
site, further corroborating a deleterious effect of the c.2484 + 5G > T change on splicing. Although
cDNA was not available to verify the c.2484 + 5G > T effect on splicing, this variant was classified as
likely pathogenic.
Because the germline mutations in the KIT gene are infrequently associated with
neurodevelopmental abnormalities, we performed an array-CGH analysis, which identified in IV-3 a
207-kb VUS (variant of unknown significance) duplication at the long arm of chromosome 3, and a
1.5-Mb deletion at the long arm of a chromosome 15: arr[GRCh37] 3q23(141,841,034-142,048,481) × 3,
15q13.2q13.3(31,014,508-32,510,863) × 1. The latter completely overlaps with the 15q13.3 microdeletion
critical region (MIM 612001). Both rearrangements were validated in the probands by quantitative
real-time PCR. The variants were excluded in both the mother and the unaffected brother.
3. Discussion
PBT is a rare autosomal dominant genodermatosis caused by mutations in the c-kit proto-oncogene,
which encodes the transmembrane receptor tyrosine kinase for mast cell growth factor (MGF, also
known as stem cell factor) [9–14]. The KIT receptor and its ligand (KITLG) act as crucial factors in
the control of physiological and pathological skin pigmentation through the Ras ⁄ mitogen-activated
protein kinase (MAPK) signaling pathway. Accordingly, loss-of-function KIT mutations determine
defects in the survival, proliferation, differentiation, and migration of melanoblasts from the NC to
the skin during early embryonic development. Consequently, patients have a significant or complete
loss of melanocytes in the affected areas of the hair and skin [9,10]. PBT is clinically characterized by
congenital leukoderma, leukotrichia of hair, eyebrows and eyelashes, and, rarely, heterochromia of
irides, with a great variation in the degree and pattern of presentation, even within affected families.
Specifically, piebald patients are featured by congenital, well-demarked, symmetrical, non-pigmented
white patches involving the skin of the face, trunk, arms, and legs [6,9,10]. They also frequently show
poliosis, traditionally known as “white forelock”, a localized patch of white hair in a group of hair
follicle; it is often triangular in shape and may be the only manifestation of PBT in 80% to 90% of c-Kit
carriers. In some cases, both the hair and the underlying forehead may be affected [6,9]. The skin
lesions, histologically characterized by the congenital absence of melanocytes, are usually stable during
life, although hyperpigmented dots or macules may appear within or at their margins. Sometimes,
café-au-lait macules can be present in piebald patients who concomitantly may also be affected by
neurofibromatosis type 1 (NF1, MIM *613113) [9,11]. Very few piebald subjects harbor a heterozygous
change in the SNAI2 gene. It is located on chromosome 8 at position 11.21 and encodes for SNAIL2,
a protein that belongs to the Snail family of zinc finger transcription factors. SNAIL2 is involved
in the regulation of differentiation and migration of NC cells during embryonic development [4–6].
It is interesting to note that SNAI2 germline mutations in a homozygous state were reported in a few
human cases affected by a Waardenburg syndrome type 2 [7].
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We describe a large family of Albanian descent harboring a germline pathogenic change in the
KIT gene (Figure 1). Three subjects carrying the c.2484 + 5G > T splicing mutation presented skin and
hair manifestations consistent with the diagnosis of PBT and several other maternal relatives had signs
consistent with PBT. Particularly, only the probands manifested SNHL and severe intellectual disability,
which have been reported rarely in piebald patients. The first descriptions of PBT associated with
sensorineural deafness date back to the late sixties, however, these reports lack precise genetic data.
Subsequently Spritz et al. [12] described a South African female affected by severe SNHL and PBT
carrying a heterozygous missense change (p.R796G) in the KIT gene. Human homozygosity for KIT
germline mutations has been reported in a severe multisystem phenotype consisting of hypopigmented
skin and hair, blue irides, neurodevelopmental delay, hypotonia, SNHL, anemia, brachycephaly
and clinodactyly [13,14]. In view of the uniqueness of the probands’ phenotype and the rarity of
neurological manifestations in PBT, we hypothesized the presence of other genetic changes.
In effect, we also found in both probands a heterozygous deletion at chromosome 15q13.3,
overlapping to the 15q13.3 microdeletion syndrome minimal region (MIM #612001). This genomic
disorder has been associated with variable neurological and behavioral symptoms, including cognitive
impairment, epilepsy, deficits in social interaction, decreased attention spans, aggressive behaviors,
autism, schizophrenia, and bipolar disorder [17–19]. Heterozygous deletion of chromosome 15q13.3
syndrome has incomplete penetrance and up to 75% of the described affected subjects inherited the
variant from a parent with at least one of the neurodevelopmental or neuropsychiatric signs or an
apparently normal phenotype [17–19]. The family history might be compatible with this syndrome
because the deletion is likely inherited from the father, affected by severe schizophrenia. Interestingly,
a paternal uncle was reported to be affected by depression.
As regards SNHL, it has never been described in association with the 15q13.3 microdeletion
syndrome, despite its broad phenotypic spectrum. In conclusion, even though the presence of a third
unidentified (probably autosomal recessive) genetic determinant cannot be excluded with certainty,
our piebald probands could represent the second description of SNHL in carriers of a heterozygous
germline mutation in KIT gene.
4. Conclusions
We describe a novel example of a complex disease in two twins, tracked back to at least two different
autosomal dominant diseases which are maternally inherited PBT associated with KIT mutation and
a 15q13.3 genomic disorder, likely inherited from the father, responsible for a neurodevelopmental
disease with variable expressivity/incomplete penetrance.
To our best knowledge, this is the first reported phenotype due to the co-occurrence of germline
pathogenic change in the KIT gene mutation and deletion at chromosome 15q13.3.
This report follows up a recent finding on large cohorts of complex patients showing 5% of
cases having two or more genetic diseases. Our experience highlights the crucial role of genetic
analyzes in the case of a multisystem phenotype, where the presence of multilocus syndromes should
be considered [20,21]. Since two or more genetic disorders may overlap in a single individual,
combining an extremely polymorphous multisystem phenotype, the diagnostic process should involve
an interdisciplinary group of clinicians.
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